Takeda Pharmaceuticals North America, Inc. is dedicated to serving patients by providing innovative products that improve their lives with better healthcare. It is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Japan’s largest pharmaceutical company and one with a more than 227-year heritage. Takeda’s US clinical development activities are conducted via Takeda Global Research & Development Center, Inc.

Takeda focuses on a variety of therapeutic areas including diabetes, cardiovascular disease, central nervous system disorders, gastroenterology, bone and joint disorders, chronic kidney disease, gynecological disorders, and infectious disease. With a promising pipeline and successful products in multiple therapeutic areas, the company is one of the fastest growing pharmaceutical companies in the United States.

Our mission is simple and compelling: we are dedicated to serving patients by providing innovative products that improve their lives with better healthcare. Our commitment to patients, employees, partners, and the larger community gives us the purpose to build on the tremendous success we enjoy as an emerging global leader in the pharmaceutical industry.

This mission:

• • Drives our research and development of prescription drugs
• • Promotes our commitment to social responsibility
• • Marks our growth and success

Our History

Over two centuries ago, a small medicine shop was opened in Doshomachi, Osaka, Japan to provide medicines to local merchants and doctors. This was the beginning of the present-day Takeda family of pharmaceutical companies. Many generations later, in 1998, Takeda Pharmaceuticals North America, Inc. (TPNA) was introduced.

In 1999, the U.S. Food and Drug Administration (FDA) approved ACTOS^® (pioglitazone HCl) for marketing in the United States. The success of ACTOS was a catalyst for the growth we continue to achieve. TPNA began with three employees in 1998; we now have more than 5,500 employees.

Takeda Global Research & Development was established in 2004 and is responsible for Takeda’s clinical research and development in the U.S. and for supporting clinical and product development activity for TPNA. With a robust pipeline of compounds in development for diabetes, cardiovascular disease and other conditions, Takeda rapidly brings innovative products to market to improve patient health and enhance the practice of medicine.

In 2008, Takeda and Abbott evenly divided their joint venture—TAP Pharmaceutical Products Inc—and the subsequent integration with two of Takeda’s wholly owned U.S. subsidiaries, TPNA and TGRD, created one of the top 15 pharmaceutical companies in the United States.

To find out more about Takeda's global operations, please visit http://www.takeda.com.